Investors

Press Releases

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Select Year
Search …

Found 340 Results

Palatin Provides Update on Anticipated 2025 Corporate Milestones

January 28, 2025

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

December 19, 2024

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

December 16, 2024

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

November 25, 2024

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

November 14, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

November 8, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

November 4, 2024

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

October 31, 2024

Inflammatory Disease Healing Data via Palatin’s Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

October 24, 2024

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

October 23, 2024

Newer

Page 3 of 34

Older